Roteas: Uses, Dosage & Side Effects
A direct oral anticoagulant (DOAC) and selective Factor Xa inhibitor used to prevent stroke in atrial fibrillation and to treat and prevent venous thromboembolism
Roteas (edoxaban) is a direct oral anticoagulant (DOAC) belonging to the class of selective Factor Xa inhibitors. It is licensed for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as the prevention of recurrent DVT and PE in adults. Roteas is taken orally once daily and does not require routine monitoring of coagulation status, representing a significant practical advantage over the traditional vitamin K antagonist warfarin. The 15 mg strength is specifically used during the transition from Roteas to warfarin therapy. Treatment must be closely supervised by a physician, and bleeding is the most clinically important risk.
Quick Facts: Roteas
Key Takeaways
- Roteas (edoxaban) is a once-daily direct oral anticoagulant that selectively inhibits Factor Xa, reducing thrombin generation and the formation of harmful blood clots without requiring routine INR monitoring.
- It is approved for stroke prevention in non-valvular atrial fibrillation and for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism in adults.
- The 15 mg tablet is a dedicated transition strength used only during the switch from Roteas to warfarin; it is not a stand-alone maintenance dose for any indication.
- The most important safety concern is bleeding; Roteas requires dose reduction in patients with moderate renal impairment, low body weight, or concomitant use of certain P-glycoprotein inhibitors such as ciclosporin, dronedarone, erythromycin, or ketoconazole.
- Roteas should not be used in patients with mechanical heart valves, moderate-to-severe mitral stenosis, or uncontrolled hypertension, and should be stopped at least 24 hours before surgery with moderate bleeding risk (48 hours for high bleeding risk).
What Is Roteas and What Is It Used For?
Roteas contains the active substance edoxaban (as edoxaban tosilate), which belongs to a group of medicines known as direct oral anticoagulants (DOACs), sometimes also called non-vitamin K oral anticoagulants (NOACs). Edoxaban is a highly selective, reversible, direct inhibitor of activated coagulation Factor X (Factor Xa). Factor Xa sits at a central position in the coagulation cascade: it is responsible for converting prothrombin to thrombin, the enzyme that ultimately transforms soluble fibrinogen into insoluble fibrin and forms a stable blood clot. By inhibiting Factor Xa, Roteas reduces thrombin generation and therefore limits the body’s ability to form pathological clots, while still permitting some level of haemostasis to continue.
The introduction of DOACs such as edoxaban, apixaban, dabigatran, and rivaroxaban has fundamentally changed anticoagulant therapy over the past decade. Compared with traditional warfarin and other vitamin K antagonists, Roteas offers several practical advantages: a rapid onset of action within 1–2 hours of oral intake, a predictable dose-response relationship, fewer food and drug interactions, and no routine requirement for coagulation monitoring such as the international normalized ratio (INR). Roteas is administered once daily, which generally improves adherence compared to medicines taken multiple times daily.
Roteas is authorized by the European Medicines Agency (EMA) in the European Union and by multiple regulatory agencies worldwide for the following indications in adult patients:
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF): Roteas is used in adults with NVAF who have one or more risk factors for thromboembolism, such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Atrial fibrillation is the most common sustained cardiac arrhythmia and significantly increases the risk of thromboembolic stroke caused by clots formed in the left atrial appendage.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE): Roteas is used to treat established DVT, where a blood clot has formed in a deep vein (usually in the leg), and PE, where a clot has travelled to the lungs. Treatment prevents existing clots from growing larger and reduces the risk of new clots forming.
- Prevention of recurrent DVT and PE: Roteas is used to reduce the risk of a subsequent venous thromboembolic event in adults who have already experienced an acute DVT or PE. This long-term prevention is particularly important because approximately 20–30% of patients with a first unprovoked VTE will experience recurrence within five years without continued anticoagulation.
The clinical evidence base for Roteas comes from large, international randomized controlled trials. In the ENGAGE AF-TIMI 48 study, a landmark head-to-head comparison of edoxaban against warfarin in more than 21,000 patients with non-valvular atrial fibrillation, edoxaban 60 mg once daily was non-inferior to dose-adjusted warfarin for the prevention of stroke or systemic embolism, and demonstrated significantly lower rates of major bleeding, intracranial haemorrhage, and cardiovascular mortality. In the Hokusai-VTE trial involving more than 8,000 patients with acute symptomatic venous thromboembolism, edoxaban was non-inferior to warfarin for the prevention of recurrent VTE and was associated with significantly less clinically relevant bleeding.
Although Roteas shares the 15 mg, 30 mg, and 60 mg tablet strengths with other edoxaban products such as Lixiana and Savaysa, Roteas is a distinct authorized medicine in its own right, marketed in selected European countries. Healthcare professionals and patients should be aware that all of these products contain the same active substance and follow the same clinical dosing principles.
Unlike warfarin, which inhibits multiple clotting factors through vitamin K, Roteas has a single, targeted action on Factor Xa. This means its anticoagulant effect is highly predictable, starts within hours rather than days, and does not require routine INR monitoring, frequent dose adjustments, or strict dietary vitamin K restrictions. However, this lack of monitoring means patients and clinicians must rely on clinical vigilance for safety, and adherence to the prescribed dose becomes critically important.
What Should You Know Before Taking Roteas?
Contraindications
There are specific conditions in which Roteas must not be used. These absolute contraindications exist because the risks of treatment in these situations would outweigh any possible clinical benefit.
- Hypersensitivity: Do not take Roteas if you are allergic to edoxaban or any of the excipients in the tablet, including mannitol, pregelatinized starch, crospovidone, hydroxypropyl cellulose, magnesium stearate, talc, and the film-coating ingredients.
- Active, clinically significant bleeding: Roteas must not be used in patients with ongoing serious bleeding, such as gastrointestinal haemorrhage, intracranial haemorrhage, or other sources of major blood loss.
- Lesions or conditions considered a significant risk factor for major bleeding: These include current or recent gastrointestinal ulceration, the presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk: This includes advanced cirrhosis classified as Child-Pugh C.
- Uncontrolled severe hypertension: Patients with blood pressure that cannot be adequately controlled are at increased risk of haemorrhagic complications, particularly intracranial haemorrhage.
- Concomitant use of other anticoagulants: Roteas should not be given together with unfractionated heparin, low-molecular-weight heparins, heparin derivatives, other direct oral anticoagulants, or vitamin K antagonists, except in the specific clinical circumstances of switching between anticoagulant therapies under medical supervision.
- Pregnancy and breast-feeding: Roteas is not recommended during pregnancy or breastfeeding, as safety has not been established in these populations.
- Mechanical prosthetic heart valves and moderate-to-severe mitral stenosis: DOACs, including Roteas, are ineffective and potentially dangerous in these patients; warfarin remains the anticoagulant of choice.
Warnings and Precautions
The most important safety concern with Roteas is bleeding. You should contact emergency medical services immediately if you experience: sudden severe headache or weakness (possible intracranial haemorrhage); bloody or black, tarry stools; coughing up or vomiting blood (including a coffee-ground appearance); unexplained and significant bruising; unusual or prolonged nosebleeds or bleeding from the gums; red or dark-brown urine; heavy or prolonged menstrual bleeding; or any bleeding that will not stop.
Before starting Roteas and during ongoing treatment, tell your doctor if any of the following apply to you:
- Kidney function: Roteas is partially eliminated by the kidneys. Your doctor will assess renal function before starting treatment and will reassess it periodically. In patients with non-valvular atrial fibrillation and very high creatinine clearance (above 95 mL/min), Roteas has been associated with a lower efficacy compared with well-controlled warfarin and should not be used.
- Liver disease: Moderate or severe liver impairment, or any elevation of liver enzymes, should be disclosed to your doctor. Roteas is not recommended in patients with severe hepatic impairment.
- Low body weight: Patients weighing 60 kg or less generally require a lower dose to reduce bleeding risk.
- Older age: Increasing age, particularly in patients 75 years and above, is associated with higher bleeding risk. Careful dose selection and close monitoring are essential in this group.
- Prior history of bleeding: Inform your doctor of any previous episodes of gastrointestinal, intracranial, or other significant bleeding.
- Upcoming surgery or invasive procedures: Tell any healthcare professional treating you, including dentists, that you are taking Roteas. Most planned procedures require a pause in therapy to reduce bleeding risk.
- Antiphospholipid syndrome (APS): DOACs are not recommended for patients with triple-positive antiphospholipid syndrome, because warfarin has shown superior outcomes in these high-risk patients.
- Spinal or epidural anaesthesia: The combination of Roteas with neuraxial anaesthesia or lumbar puncture may result in epidural or spinal haematoma and permanent paralysis. Strict timing rules apply and must be followed.
- Indwelling epidural or intrathecal catheters: Should not be present while you are taking Roteas. Timing of catheter removal and re-dosing must follow specialist protocols.
Your doctor will periodically assess your kidney and liver function, as well as your overall bleeding risk, using tools such as the HAS-BLED score for atrial fibrillation patients. Any new symptoms suggestive of bleeding should be reported immediately.
Pregnancy, Breastfeeding and Fertility
The safety and efficacy of Roteas during pregnancy have not been established. Animal studies have shown reproductive toxicity. Roteas should not be used during pregnancy, and women of childbearing potential should avoid becoming pregnant during treatment. Effective contraception is recommended throughout therapy and for a period afterwards, as advised by the prescribing physician.
It is not known whether edoxaban is excreted in human breast milk. Animal data indicate that edoxaban is excreted in the milk of lactating rats. Breastfeeding should be discontinued during treatment with Roteas. There is no evidence that Roteas affects fertility in men or women.
Driving and Operating Machinery
Roteas has no or negligible direct influence on the ability to drive or use machinery. However, if you experience dizziness, confusion, or any symptoms of bleeding that could impair your ability to operate a vehicle or equipment safely, you should refrain from driving or using machinery until you have discussed the symptoms with your doctor.
How Does Roteas Interact with Other Drugs?
Edoxaban is primarily absorbed through the gut and eliminated through a combination of hepatic metabolism and direct renal excretion. It is a substrate of the P-glycoprotein (P-gp) efflux transporter but not of cytochrome P450 enzymes to a clinically significant degree. This pharmacological profile explains the specific pattern of interactions seen with Roteas: drugs that strongly inhibit or induce P-gp can alter edoxaban concentrations, while drugs with a shared risk of bleeding contribute to cumulative pharmacodynamic toxicity. It is essential to inform your doctor and pharmacist of every medicine, supplement, and herbal product you use.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Ciclosporin, dronedarone, erythromycin, ketoconazole (P-gp inhibitors) | Increased edoxaban plasma levels and bleeding risk | Reduce Roteas dose to 30 mg once daily (AF, DVT/PE treatment) or 15 mg once daily where applicable |
| Rifampicin, phenytoin, carbamazepine, St John’s wort (P-gp inducers) | Decreased edoxaban plasma levels, potentially reduced efficacy | Use with caution; therapeutic alternatives should be considered |
| Other anticoagulants (heparins, LMWH, warfarin, other DOACs) | Severely increased bleeding risk | Contraindicated except during supervised therapy switching |
| Aspirin (>100 mg/day) and dual antiplatelet therapy | Significantly increased bleeding risk | Avoid unless clearly indicated; careful benefit/risk assessment required |
| Clopidogrel, prasugrel, ticagrelor (antiplatelet agents) | Additive bleeding risk | Triple therapy should be limited to shortest effective duration |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Increased risk of gastrointestinal bleeding | Avoid chronic use; prefer paracetamol for analgesia where possible |
Other Important Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Amiodarone, quinidine, verapamil (mild P-gp inhibitors) | Mild increase in edoxaban exposure | No routine dose adjustment required; monitor for bleeding |
| SSRIs, SNRIs (e.g., sertraline, venlafaxine) | Possibly increased bleeding risk, especially gastrointestinal | Use with caution; inform doctor of new bleeding symptoms |
| Corticosteroids (systemic) | Increased gastrointestinal bleeding risk in combination with NSAIDs or anticoagulants | Avoid combinations where possible; consider gastroprotective therapy |
| Digoxin (P-gp substrate) | No clinically significant interaction observed | No dose adjustment required |
| Proton pump inhibitors, H2-blockers, antacids | No clinically significant effect on edoxaban absorption | Can be co-administered; may help protect against upper GI bleeding |
| Herbal products (St John’s wort, ginkgo, garlic, ginger) | St John’s wort induces P-gp; other herbs may affect bleeding | Disclose all herbal products; avoid St John’s wort during treatment |
Food does not significantly affect the absorption or bioavailability of Roteas, so the tablet may be taken with or without meals. Grapefruit and grapefruit juice do not require avoidance, because edoxaban is not significantly metabolized through the CYP3A4 pathway. Alcohol consumption in moderation does not directly alter edoxaban levels, but heavy alcohol use is associated with an independent increase in bleeding risk and can impair liver function, so moderate intake is advised.
Show a full, up-to-date list of your medicines, including over-the-counter products, vitamins, and herbal supplements, to any doctor, dentist, or pharmacist who treats you. Even medicines that seem harmless can interact with Roteas and change your bleeding risk. Carry an anticoagulant alert card if one has been provided.
What Is the Correct Dosage of Roteas?
Roteas tablets should be swallowed whole with a glass of water, with or without food. The tablet can be taken at any time of day, but it is important to take it at approximately the same time each day to maintain stable anticoagulation. Patients who have difficulty swallowing may crush the tablet and mix it with water or an aqueous apple puree immediately before administration. The crushed tablet can also be dispersed in water and given via a nasogastric tube, where clinically appropriate. The individual dose and duration will be determined by your doctor based on the indication, your body weight, kidney function, and any concomitant medications.
Adults – Standard Dosing
Non-Valvular Atrial Fibrillation (NVAF)
Standard dose: 60 mg once daily
Reduced dose: 30 mg once daily in patients with any of the following: creatinine clearance 15–50 mL/min, body weight ≤60 kg, or concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole.
Duration: Long-term, as stroke prevention in atrial fibrillation typically continues lifelong unless a specific reason for discontinuation arises.
Treatment of DVT and PE and Prevention of Recurrence
Initial therapy: Start with a parenteral anticoagulant (e.g., low-molecular-weight heparin) for at least 5 days, then switch to Roteas.
Standard dose: 60 mg once daily
Reduced dose: 30 mg once daily in patients with creatinine clearance 15–50 mL/min, body weight ≤60 kg, or concomitant use of specified strong P-gp inhibitors.
Duration: At least 3 months. Longer-term treatment is individualised based on ongoing risk of recurrence and bleeding.
Transition from Roteas to Warfarin
Standard method (patients on 60 mg Roteas): Reduce Roteas to 30 mg once daily and start warfarin concurrently. Measure INR immediately before the Roteas dose.
Patients on 30 mg Roteas: Reduce Roteas to 15 mg once daily and start warfarin concurrently.
Stopping criterion: Discontinue Roteas once the INR is ≥2.0.
Duration of overlap: Up to 14 days; if the INR has not reached 2.0 by day 14, Roteas should be stopped and INR monitored without further Roteas dosing.
Elderly Patients
No specific starting-dose adjustment is required based on age alone. However, clinicians should carefully assess age-related decline in kidney function, low body weight, and polypharmacy, all of which may necessitate the 30 mg dose. Elderly patients are at higher baseline bleeding risk and should be monitored closely, particularly during the first few months of treatment and after any clinical change such as acute illness, hospitalisation, or initiation of a new interacting medicine.
Renal Impairment
| Creatinine Clearance | Recommended Dose (AF, DVT/PE) | Comment |
|---|---|---|
| >95 mL/min | Not recommended in AF | Reduced efficacy compared to warfarin in this group |
| 51–95 mL/min | 60 mg once daily | Standard dose |
| 30–50 mL/min | 30 mg once daily | Moderate impairment; reduced dose |
| 15–29 mL/min | 30 mg once daily | Severe impairment; use with caution |
| <15 mL/min or dialysis | Not recommended | Insufficient clinical data |
Hepatic Impairment
No dose adjustment is required in patients with mild hepatic impairment (Child-Pugh A). In moderate hepatic impairment (Child-Pugh B), Roteas should be used with caution. In severe hepatic impairment (Child-Pugh C) and in any hepatic disease associated with coagulopathy and clinically relevant bleeding risk, Roteas is contraindicated. Liver function tests (ALT, AST, bilirubin) should be performed before starting treatment and periodically thereafter.
Children and Adolescents
The safety and efficacy of Roteas in children and adolescents below 18 years of age have not been established, and it is not currently recommended for use in this population outside of supervised clinical trials. Paediatric venous thromboembolism should be managed by a specialist experienced in paediatric haematology and coagulation disorders.
What To Do If a Dose Is Missed
If a dose of Roteas is missed, take it as soon as you remember on the same day, and then take the next regular dose on the following day at the usual time. Do not take two doses on the same day to make up for the missed one. Missing doses reduces the level of protection against clot formation, so consistent daily intake is essential. If you are unsure what to do, contact your pharmacist or doctor as soon as possible.
Overdose
An overdose of Roteas increases the risk of bleeding. If you or someone else has taken more Roteas than prescribed, contact emergency services or a poison control centre immediately, even in the absence of bleeding symptoms. Treatment of overdose focuses on supportive care: activated charcoal may reduce absorption if the overdose occurred within 1–2 hours. For life-threatening or uncontrolled bleeding, the specific reversal agent andexanet alfa (Ondexxya) can be used where available; alternatively, four-factor prothrombin complex concentrate (4F-PCC) may be considered. Edoxaban is approximately 55% protein-bound and is not significantly removed by haemodialysis. Routine coagulation tests such as PT or aPTT are not reliable indicators of edoxaban activity; where available, anti-Factor Xa activity calibrated for edoxaban can quantify drug exposure.
Management Around Surgery and Invasive Procedures
If you are scheduled to have surgery or any invasive procedure, tell the treating team well in advance that you are taking Roteas. As a general rule, Roteas should be stopped at least 24 hours before procedures with a low or moderate risk of bleeding and at least 48 hours before procedures with a high risk of bleeding. In patients with impaired renal function, a longer washout period may be required. Roteas can usually be restarted 6–8 hours after surgery once haemostasis is secure and full therapeutic anticoagulation can resume within 48–72 hours, depending on the bleeding risk of the procedure. Bridging with low-molecular-weight heparin is generally not required given the rapid onset and short half-life of Roteas.
Stopping Roteas suddenly increases the risk of stroke, systemic embolism, or new clots. If any surgery, dental work, or change in therapy requires a pause in anticoagulation, your doctor will plan the timing carefully. Always discuss any plan to stop or change the dose with the prescribing physician.
What Are the Side Effects of Roteas?
Like all medicines, Roteas can cause side effects, although not everyone experiences them. The overall safety profile of edoxaban has been well characterized through large clinical trials and post-marketing surveillance. The pattern of adverse effects is dominated by bleeding events, which are an expected pharmacological consequence of any anticoagulant. Non-bleeding adverse effects are generally uncommon and, when present, are usually mild to moderate in severity. The frequencies below are organized according to standard European pharmacovigilance terminology.
Side Effects Organized by Frequency
Very Common (may affect more than 1 in 10 people)
Frequency: >1/10
- Skin rash and itching (pruritus)
- Nosebleeds (epistaxis)
- Vaginal bleeding
- Bruising (contusion, ecchymosis)
- Abnormal liver function tests (elevated ALT/AST)
Common (may affect up to 1 in 10 people)
Frequency: 1/100 to 1/10
- Anaemia (reduced red blood cell count)
- Dizziness
- Headache
- Abdominal pain
- Nausea
- Gastrointestinal bleeding (blood in stools, black stools)
- Rectal bleeding
- Blood in urine (haematuria)
- Bleeding from puncture sites following injections or procedures
- Urticaria (hives)
- Abnormal blood test results (elevated bilirubin, gamma-GT, alkaline phosphatase)
Uncommon (may affect up to 1 in 100 people)
Frequency: 1/1,000 to 1/100
- Hypersensitivity reactions (allergic skin reactions)
- Intracranial haemorrhage (bleeding inside the skull)
- Conjunctival or scleral haemorrhage (bleeding inside the eye)
- Haemoptysis (coughing up blood)
- Subcutaneous haematoma (bleeding under the skin causing a lump)
- Intraocular haemorrhage
- Surgical-site bleeding
- Other types of wound bleeding
Rare (may affect up to 1 in 1,000 people)
Frequency: 1/10,000 to 1/1,000
- Anaphylactic reaction (severe allergic reaction)
- Allergic oedema (swelling of face, lips, tongue, or throat)
- Subarachnoid haemorrhage
- Pericardial haemorrhage
- Retroperitoneal haemorrhage
- Intramuscular haemorrhage (not associated with compartment syndrome)
- Intra-articular haemorrhage (bleeding into joints)
- Subdural haemorrhage
- Procedural haemorrhage
Not Known (frequency cannot be estimated from available data)
Frequency: Unknown
- Thrombocytopenia (reduced platelet count)
- Idiosyncratic hepatic reactions
- Drug-induced liver injury
Recognising Serious Side Effects
Any new or unexplained bleeding during Roteas therapy should prompt evaluation. Seek immediate emergency medical attention if you experience any of the following: sudden severe headache, unilateral weakness, slurred speech, loss of consciousness, or visual disturbances (potential signs of intracranial haemorrhage); vomiting blood or coffee-ground material; passing black, tarry, or bloody stools; severe abdominal pain; heavy or prolonged menstrual bleeding; severe nosebleeds that cannot be controlled; blood in urine, sputum, or vomit; unexplained fainting; or unusually extensive bruising without trauma.
Less urgent but important symptoms include: minor persistent nosebleeds, gum bleeding on brushing, small bruises, rash, itching, dizziness, unusual fatigue (possible anaemia from slow bleeding), or any new skin changes. These should be discussed with your doctor during routine appointments, but do not require emergency care unless they are severe or progressive.
If you or someone taking Roteas develops sudden severe headache, one-sided weakness or numbness, speech difficulty, confusion, visual loss, or loss of consciousness, call emergency services immediately. Rapid imaging and, if appropriate, administration of a reversal agent can reduce the risk of permanent injury or death.
Reporting Side Effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed here. You can also report side effects directly via your national pharmacovigilance system (e.g., MHRA Yellow Card Scheme in the UK, EMA EudraVigilance in the EU, FDA MedWatch in the US). Reporting side effects helps authorities monitor the long-term safety of medicines and protect future patients.
How Should You Store Roteas?
Proper storage of Roteas ensures the stability and effectiveness of each tablet throughout its shelf life. The film-coated tablet formulation is designed to be stored under ordinary household conditions without special cold chain requirements, but some general principles should be observed:
- Temperature: Store below 25°C (77°F). The product has been shown to remain stable at normal room temperatures. Do not refrigerate.
- Humidity and light: Keep Roteas tablets in the original aluminium blister pack until the moment of use to protect them from moisture. Do not transfer tablets into pill organisers that expose them to air and humidity for extended periods.
- Childproofing: Store Roteas out of the sight and reach of children. Even a single tablet can cause harm if accidentally ingested by a child. Use child-resistant cupboards where possible.
- Expiry date: Do not use Roteas after the expiry date stated on the carton and blister pack after “EXP.” The expiry date refers to the last day of the stated month.
- Travel: When travelling, keep tablets in their original packaging in carry-on luggage to avoid exposure to extreme temperatures in checked baggage or cargo holds. Take a sufficient supply plus a few extra days’ worth to cover unexpected travel delays.
Safe Disposal
Do not throw away medicines via wastewater or household waste. Unused or expired Roteas tablets should be returned to a pharmacy or a designated medicines take-back scheme. These measures help protect the environment, because pharmaceutical residues in wastewater can affect aquatic life and ecosystems.
What Does Roteas Contain?
Active Substance
Each Roteas 15 mg film-coated tablet contains edoxaban tosilate monohydrate equivalent to 15 mg of edoxaban. Other tablet strengths of Roteas contain 30 mg or 60 mg of edoxaban per tablet.
Inactive Ingredients (Excipients)
Tablet core:
- Mannitol (E421)
- Pregelatinized starch
- Crospovidone
- Hydroxypropyl cellulose
- Magnesium stearate
- Talc
Film coating:
- Hypromellose (E464)
- Macrogol 8000
- Titanium dioxide (E171)
- Talc
- Carnauba wax
- Iron oxide yellow (E172) – colour varies with strength; 15 mg tablets are typically pale yellow-orange
- Iron oxide red (E172) in some strengths
Appearance and Packaging
Roteas 15 mg film-coated tablets are round, biconvex, film-coated tablets with characteristic debossing identifying the strength. The visual appearance differs between the 15 mg, 30 mg, and 60 mg tablets to help patients and healthcare professionals distinguish strengths at a glance. Tablets are supplied in aluminium-aluminium blister packs of varying sizes (typically 10, 14, 28, 30, 56, 60, 90, or 98 tablets). Not all pack sizes may be marketed in every country.
Marketing Authorization Holder
Roteas is marketed by Daiichi Sankyo Europe GmbH in several European countries. The global development of edoxaban has been led by Daiichi Sankyo, and equivalent edoxaban products are marketed under other trade names (e.g., Lixiana in many European countries, Savaysa in the United States). Check the patient information leaflet accompanying your pack for the current marketing authorisation holder and local representative.
Roteas tablets do not contain gluten or lactose, and the excipient list does not include ingredients of animal origin. This makes Roteas suitable for patients with coeliac disease, lactose intolerance, or those following a vegan or vegetarian lifestyle.
Frequently Asked Questions About Roteas
Roteas (edoxaban) is a direct oral anticoagulant used to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation who have one or more risk factors. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent recurrent DVT and PE in adults. Roteas works by blocking Factor Xa, a key protein in the blood clotting process, thereby reducing the formation of harmful blood clots.
Take Roteas once daily at approximately the same time each day, with or without food. Swallow the tablet whole with a glass of water. If you have difficulty swallowing, the tablet may be crushed and mixed with water or a small amount of apple puree immediately before administration. Do not stop taking Roteas without consulting your doctor, as stopping suddenly may increase your risk of stroke or blood clots.
The most common side effects of Roteas are related to bleeding, including nosebleeds, bruising, rash, itching, abnormal liver function tests, blood in urine, vaginal bleeding, and gastrointestinal bleeding. Anaemia, dizziness, headache, nausea, and abdominal pain are also common. Most bleeding is minor, but severe or uncontrolled bleeding can occur and requires immediate medical attention.
The Roteas 15 mg tablet is not used as a stand-alone maintenance dose. It is specifically used during the transition from Roteas back to warfarin (vitamin K antagonist therapy). During this switch, patients take Roteas 15 mg together with an appropriate dose of warfarin for up to 14 days, or until the INR reaches 2.0 or higher, to ensure continuous anticoagulation protection.
Combining Roteas with aspirin, clopidogrel, NSAIDs (such as ibuprofen, naproxen, or diclofenac), or similar medicines increases the risk of bleeding and should generally be avoided unless clearly indicated and supervised by a doctor. For occasional pain or fever, paracetamol is usually a safer alternative. Always inform your healthcare provider of every medicine you take, including over-the-counter products and herbal remedies.
If you miss a dose of Roteas, take it as soon as you remember on the same day, then continue taking your regular dose the following day. Do not take a double dose on the same day to make up for a forgotten dose. If you are unsure what to do, contact your pharmacist or doctor. Missing doses reduces protection against stroke or blood clots, so consistent daily intake is important.
Andexanet alfa (Ondexxya) is a specific reversal agent approved in the EU and US for patients treated with edoxaban who experience life-threatening or uncontrolled bleeding. In settings where andexanet alfa is unavailable, four-factor prothrombin complex concentrate (4F-PCC) can be considered. Activated charcoal may reduce absorption if edoxaban was ingested within the last 1–2 hours. Edoxaban is not significantly removed by haemodialysis.
Unlike warfarin, Roteas does not require routine INR monitoring. However, your doctor will check your kidney function (creatinine clearance) and liver function before starting treatment and periodically thereafter. Regular blood counts may also be done to look for anaemia or hidden bleeding. If you have a significant change in health – such as acute illness, weight loss, or a new medication – additional testing may be needed.
References
- European Medicines Agency (EMA). Roteas (edoxaban) – Summary of Product Characteristics. Last updated 2025. Available from: EMA.
- U.S. Food and Drug Administration (FDA). Savaysa (edoxaban) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48). N Engl J Med. 2013;369(22):2093–2104. doi:10.1056/NEJMoa1310907.
- The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415. doi:10.1056/NEJMoa1306638.
- Van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–1975. doi:10.1182/blood-2014-04-571232.
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414. doi:10.1093/eurheartj/ehae176.
- National Institute for Health and Care Excellence (NICE). NG196: Atrial fibrillation – diagnosis and management. London: NICE; 2021 (last updated 2023).
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612–1676. doi:10.1093/europace/euab065.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors (ANNEXA-4). N Engl J Med. 2019;380(14):1326–1335. doi:10.1056/NEJMoa1814051.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026.
- Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in cardiology, haematology, and clinical pharmacology.
Medical Content
iMedic Cardiology Editorial Team – specialist physicians in cardiology and internal medicine with clinical experience in anticoagulation management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, ESC, and NICE guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.